Clinical Trials Browser

Phase 1/2 × Lymphoma × INCB039110 × Clear all

NCT02760485 2023-06-15

A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 1/2 Completed

33 enrolled 20 charts

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse